Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
Oral treprostinil (TRE) is a prostacylin that is approved for the treatment of patients with pulmonary arterial hypertension (PAH). Dosing is approved for two or three times daily (t.i.d.); however, adverse effects, including gastrointestinal-related symptoms, may limit the ability to reach optimal...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-11-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045893217744512 |